Thrombocytopenia in HIV-infected drug users in the HAART era

Ximena Burbano, Maria Jose Miguez, Robert Lecusay, Allan E Rodriguez, Phillip Ruiz, Guillermo Morales, Gloria Castillo, Marianna Baum, Gail Shor-Posner

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The present case-control study compared 26 HIV+ drug users having persistent thrombocytopenia (TCP<150 000/mm3) with 54 available age, gender and HIV CDC classification matched controls with normal platelet counts. Participants were followed longitudinally over a 2-year period (1998-2000), and hematological alterations evaluated in relationship to antiretroviral treatment, drug use and nutritional (selenium) status. Demographic information and medical history, including antiretroviral treatment were obtained. Blood was drawn for complete cell blood count, T lymphocytes and viral load. Sixty-nine percent of the individuals with persistent TCP and 49% of the controls were receiving antiretrovirals. At baseline, no significant differences in CD4 existed between the two groups. Over time, CD4 cell count declined in the cases (P = 0.05) and a significantly higher proportion of the cases (38%) developed AIDS (CD4<200 cell/mm3), as compared to the controls (18%, P = 0.004). A high risk for development of thrombocytopenia was observed with specific drug use (heroin 2.96 times, P = 0.0007), selenium levels below 145 μg/l (6 times, P = 0.008), and abnormal liver enzyme (SGOT) levels (2 times, P = 0.002). Together, these results indicate a number of factors that may be sensitive predictors of thrombocytopenia, which, despite antiretroviral treatment, appears to be related to more rapid disease progression in drug users.

Original languageEnglish
Pages (from-to)456-461
Number of pages6
JournalPlatelets
Volume12
Issue number8
DOIs
StatePublished - Dec 1 2001

Fingerprint

Highly Active Antiretroviral Therapy
Drug Users
Thrombocytopenia
HIV
Selenium
Blood Cell Count
Heroin
Centers for Disease Control and Prevention (U.S.)
CD4 Lymphocyte Count
Aspartate Aminotransferases
Viral Load
Nutritional Status
Platelet Count
Pharmaceutical Preparations
Disease Progression
Case-Control Studies
Acquired Immunodeficiency Syndrome
Therapeutics
Cell Count
Demography

ASJC Scopus subject areas

  • Hematology
  • Cell Biology

Cite this

Burbano, X., Miguez, M. J., Lecusay, R., Rodriguez, A. E., Ruiz, P., Morales, G., ... Shor-Posner, G. (2001). Thrombocytopenia in HIV-infected drug users in the HAART era. Platelets, 12(8), 456-461. https://doi.org/10.1080/09537100120093956

Thrombocytopenia in HIV-infected drug users in the HAART era. / Burbano, Ximena; Miguez, Maria Jose; Lecusay, Robert; Rodriguez, Allan E; Ruiz, Phillip; Morales, Guillermo; Castillo, Gloria; Baum, Marianna; Shor-Posner, Gail.

In: Platelets, Vol. 12, No. 8, 01.12.2001, p. 456-461.

Research output: Contribution to journalArticle

Burbano, X, Miguez, MJ, Lecusay, R, Rodriguez, AE, Ruiz, P, Morales, G, Castillo, G, Baum, M & Shor-Posner, G 2001, 'Thrombocytopenia in HIV-infected drug users in the HAART era', Platelets, vol. 12, no. 8, pp. 456-461. https://doi.org/10.1080/09537100120093956
Burbano, Ximena ; Miguez, Maria Jose ; Lecusay, Robert ; Rodriguez, Allan E ; Ruiz, Phillip ; Morales, Guillermo ; Castillo, Gloria ; Baum, Marianna ; Shor-Posner, Gail. / Thrombocytopenia in HIV-infected drug users in the HAART era. In: Platelets. 2001 ; Vol. 12, No. 8. pp. 456-461.
@article{a95ea7d2f367431589ac0ad6f6ccd7aa,
title = "Thrombocytopenia in HIV-infected drug users in the HAART era",
abstract = "The present case-control study compared 26 HIV+ drug users having persistent thrombocytopenia (TCP<150 000/mm3) with 54 available age, gender and HIV CDC classification matched controls with normal platelet counts. Participants were followed longitudinally over a 2-year period (1998-2000), and hematological alterations evaluated in relationship to antiretroviral treatment, drug use and nutritional (selenium) status. Demographic information and medical history, including antiretroviral treatment were obtained. Blood was drawn for complete cell blood count, T lymphocytes and viral load. Sixty-nine percent of the individuals with persistent TCP and 49{\%} of the controls were receiving antiretrovirals. At baseline, no significant differences in CD4 existed between the two groups. Over time, CD4 cell count declined in the cases (P = 0.05) and a significantly higher proportion of the cases (38{\%}) developed AIDS (CD4<200 cell/mm3), as compared to the controls (18{\%}, P = 0.004). A high risk for development of thrombocytopenia was observed with specific drug use (heroin 2.96 times, P = 0.0007), selenium levels below 145 μg/l (6 times, P = 0.008), and abnormal liver enzyme (SGOT) levels (2 times, P = 0.002). Together, these results indicate a number of factors that may be sensitive predictors of thrombocytopenia, which, despite antiretroviral treatment, appears to be related to more rapid disease progression in drug users.",
author = "Ximena Burbano and Miguez, {Maria Jose} and Robert Lecusay and Rodriguez, {Allan E} and Phillip Ruiz and Guillermo Morales and Gloria Castillo and Marianna Baum and Gail Shor-Posner",
year = "2001",
month = "12",
day = "1",
doi = "10.1080/09537100120093956",
language = "English",
volume = "12",
pages = "456--461",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Thrombocytopenia in HIV-infected drug users in the HAART era

AU - Burbano, Ximena

AU - Miguez, Maria Jose

AU - Lecusay, Robert

AU - Rodriguez, Allan E

AU - Ruiz, Phillip

AU - Morales, Guillermo

AU - Castillo, Gloria

AU - Baum, Marianna

AU - Shor-Posner, Gail

PY - 2001/12/1

Y1 - 2001/12/1

N2 - The present case-control study compared 26 HIV+ drug users having persistent thrombocytopenia (TCP<150 000/mm3) with 54 available age, gender and HIV CDC classification matched controls with normal platelet counts. Participants were followed longitudinally over a 2-year period (1998-2000), and hematological alterations evaluated in relationship to antiretroviral treatment, drug use and nutritional (selenium) status. Demographic information and medical history, including antiretroviral treatment were obtained. Blood was drawn for complete cell blood count, T lymphocytes and viral load. Sixty-nine percent of the individuals with persistent TCP and 49% of the controls were receiving antiretrovirals. At baseline, no significant differences in CD4 existed between the two groups. Over time, CD4 cell count declined in the cases (P = 0.05) and a significantly higher proportion of the cases (38%) developed AIDS (CD4<200 cell/mm3), as compared to the controls (18%, P = 0.004). A high risk for development of thrombocytopenia was observed with specific drug use (heroin 2.96 times, P = 0.0007), selenium levels below 145 μg/l (6 times, P = 0.008), and abnormal liver enzyme (SGOT) levels (2 times, P = 0.002). Together, these results indicate a number of factors that may be sensitive predictors of thrombocytopenia, which, despite antiretroviral treatment, appears to be related to more rapid disease progression in drug users.

AB - The present case-control study compared 26 HIV+ drug users having persistent thrombocytopenia (TCP<150 000/mm3) with 54 available age, gender and HIV CDC classification matched controls with normal platelet counts. Participants were followed longitudinally over a 2-year period (1998-2000), and hematological alterations evaluated in relationship to antiretroviral treatment, drug use and nutritional (selenium) status. Demographic information and medical history, including antiretroviral treatment were obtained. Blood was drawn for complete cell blood count, T lymphocytes and viral load. Sixty-nine percent of the individuals with persistent TCP and 49% of the controls were receiving antiretrovirals. At baseline, no significant differences in CD4 existed between the two groups. Over time, CD4 cell count declined in the cases (P = 0.05) and a significantly higher proportion of the cases (38%) developed AIDS (CD4<200 cell/mm3), as compared to the controls (18%, P = 0.004). A high risk for development of thrombocytopenia was observed with specific drug use (heroin 2.96 times, P = 0.0007), selenium levels below 145 μg/l (6 times, P = 0.008), and abnormal liver enzyme (SGOT) levels (2 times, P = 0.002). Together, these results indicate a number of factors that may be sensitive predictors of thrombocytopenia, which, despite antiretroviral treatment, appears to be related to more rapid disease progression in drug users.

UR - http://www.scopus.com/inward/record.url?scp=0035662431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035662431&partnerID=8YFLogxK

U2 - 10.1080/09537100120093956

DO - 10.1080/09537100120093956

M3 - Article

C2 - 11798394

AN - SCOPUS:0035662431

VL - 12

SP - 456

EP - 461

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 8

ER -